Fukuda Denshi USA adds Senzime’s next-gen TetraGraph to U.S. portfolio

By AI, Created 9:51 PM UTC, May 28, 2026, /AGP/ – Fukuda Denshi USA says the next-generation TetraGraph neuromuscular monitoring system is now available in the United States, widening access to EMG-based anesthesia monitoring for hospitals and clinicians. The move is aimed at improving dosing, intubation readiness, and reversal decisions in perioperative care.

Why it matters: - The availability of Senzime’s Next-Generation TetraGraph® through Fukuda Denshi USA gives U.S. anesthesia teams another quantitative EMG-based option for neuromuscular monitoring. - The system is designed to help clinicians make more precise dosing and reversal decisions, which can support safer perioperative care and more consistent workflows.

What happened: - Fukuda Denshi USA announced on June 1, 2026, that the Next-Generation TetraGraph® Neuromuscular Monitoring System is now available in the United States. - The rollout expands access for anesthesia providers and hospitals through Fukuda Denshi USA’s existing purchasing pathways, clinical education and customer support resources. - The company also said the product line now broadens its anesthesia and perioperative monitoring portfolio.

The details: - The system provides real-time quantitative monitoring of neuromuscular function using EMG technology. - It supports Train-of-Four (TOF), Post-Tetanic Count (PTC) and Single Twitch (ST) monitoring. - The monitoring tools are intended to help clinicians optimize neuromuscular blocking agent dosing, assess intubation readiness and guide reversal and recovery. - The platform includes Senzime’s Level-of-Block Gauge™ and TetraGraph® Adaptive Intelligence™ technology. - The system is designed to provide intuitive visualization, workflow support and signal optimization. - Fukuda Denshi USA described the device as portable and clinician-focused for use in operating room environments. - For more information, see the company’s product page.

Between the lines: - The partnership signals a push toward more objective neuromuscular monitoring in anesthesia, moving clinicians away from subjective assessment toward quantitative data. - The U.S. distribution agreement also gives Senzime a broader route into hospitals by using Fukuda Denshi USA’s sales and support infrastructure. - The companies framed the move as both a patient-safety play and a workflow-efficiency upgrade.

What’s next: - Fukuda Denshi USA and Senzime said they plan to use the collaboration to expand access to advanced neuromuscular monitoring solutions. - Hospitals can expect the product to be supported through clinical education and customer service resources already tied to Fukuda Denshi USA. - The broader goal is to increase adoption of EMG-based monitoring across the perioperative continuum.

The bottom line: - The U.S. launch gives anesthesia teams a new distribution channel for a next-generation quantitative monitoring system built to improve decision-making in the operating room.